<DOC>
	<DOCNO>NCT01712204</DOCNO>
	<brief_summary>Initiation ULT gout increase occurrence acute gouty arthritis flare due mobilization urate tissue deposit . IL-1β play key role mediate inflammatory response gouty arthritis . The efficacy IL-1β blockade prophylaxis gouty flare initiation ULT validate multiple trial IL-1β inhibitor therapy . Therefore , believe IL-1β relevant therapeutic target gout flare . AC-201 IL-1β modulator indicate treatment osteoarthritis good safety record contraindication co-morbidities commonly among gout patient . AC-201 also demonstrate uric acid-lowering effect clinical trial . The favorable product profile AC-201 overall provide strong rationale investigate clinical utility prophylaxis flare initiate ULT .</brief_summary>
	<brief_title>A Proof-of-Concept Study AC-201 Prevent Gout Flares</brief_title>
	<detailed_description>Clinical trial demonstrate anti-IL-1 agent ( IL-1Ra , IL-1 Trap , anti-IL-1β monoclonal antibody ) reduce frequency gout flare initial period treatment urate-lowering therapy prevent gout flare gout patient frequent flare . AC-201 oral IL-1 modulator mechanism distinct exist anti-IL-1 agent . The active metabolite AC-201 show vitro vivo inhibit production activity IL-1 , down-regulate IL-1 receptor , increase IL1-Ra . Molecular research suggest effect mediate upstream via inhibition MAPK signal pathway bind NF-κB AP-1 transcription factor encode range pro-inflammatory factor , include IL-1β , TNF-α , IL-6 , IL-8 , iNOS , MMPs , implicate gout flare . AC-201 also demonstrate uric acid-lowering effect clinical trial . The favorable product profile AC-201 overall provide strong rationale investigate clinical utility prophylaxis flare initiate ULT .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Male female age 20 80 year , inclusive Meets least 6 12 American College Rheumatology preliminary criterion ( 1977 ) classification acute arthritis primary gout , OR proven tophus documented monosodium urate ( MSU ) crystal joint fluid Serum uric acid ≥7.5 mg/dL screen Experienced ≥2 gouty arthritis flare within one year prior screen Occurrence gouty arthritis flare ongoing screen screening period baseline Use allopurinol , febuxostat , benzbromarone , probenecid , sulfinpyrazone within 4 week prior screen Use colchicine , glucocorticoid , NSAIDs , COX2 inhibitor within 1 week prior screen Other ( nongout ) chronic arthritis , acute inflammatory arthritis , autoimmune disease arthritis , condition require chronic daily use pain medication History allergy component study medication , include diacerein Allergy , contraindication , intolerance febuxostat Contraindication allergy NSAIDs Severe renal impairment Any prior use biologic antiinflammatory therapy , IL1 modulators , tumor necrosis factor inhibitor , IL6 inhibitor , Tcell costimulation modulator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Prophylaxis Acute Gout Flares</keyword>
	<keyword>Urate-Lowering Therapy</keyword>
	<keyword>Hyperuricemia</keyword>
	<keyword>Gouty arthritis</keyword>
</DOC>